At a glance
ClinicalIndex Comparison RecordN/ANot Yet Recruiting· 400 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real-world Study of Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With Antibody-drug Conjugates
In Brief
An observational study for Treatment Efficacy. Not yet recruiting, targeting 400 participants.
Detailed Summary
This study is a real-world study. we collected patients with advanced HER2-negative breast cancer previously treated with antibody-drug conjugates, and received eribulin mesylate-based therapy post-ADC. We retrospectively collect the data on previous systemic treatment, and prospectively collect the treatment data of the therapeutic regimens based on eribulin mesylate.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsTreatment Efficacy
Countries--
Collaborators--
Timeline
N/ANot Yet Recruiting
20272028
Enrollment StartMar 2026
First PostedMar 2026
TodayJul 2026
Primary CompletionDec 2027
Study CompletionFeb 2028
First PostedMar 18, 2026
Enrollment StartMar 1, 2026
Primary CompletionDec 1, 2027
Study CompletionFeb 1, 2028
TodayJul 1, 2026
Enrollment to primary: 1.8 yearsPosted 3 months agoPrimary completion in 1.4 years